Press releases

Disruptive Pharma continues to grow its team with the addition of Rosita Pettersson Kneiszl as Formulation Scientist, strengthening our formulation development capabilities as we advance Formulite® and expand our work with pharmaceutical and biotechnology partners.

Disruptive Pharma will attend BIO-Europe 2026 in Cologne on 9–11 November to meet with pharmaceutical and biotechnology companies and explore development collaborations around Formulite®, our clinically evaluated formulation platform for oral small molecules. BIO-Europe is one of Europe’s leading life science partnering events, bringing...

As the pharmaceutical industry gathered at CPHI Milan 2026 this week, formulation challenges associated with increasingly complex drug compounds were clearly part of the broader industry conversation. Poor aqueous solubility remains one of the most persistent challenges in small molecule drug development. But the discussion around formulation...

Disruptive Pharma will attend CPHI Milan on 6–8 October, one of the pharmaceutical industry’s leading global events, bringing together companies from across the pharma value chain. Peter Åsberg, CEO of Disruptive Pharma, will be at CPHI to meet with current and potential partners and discuss opportunities around Formulite®, our formulation...

Disruptive Pharma AB (publ) ("Disruptive Pharma" or the "Company") today announced that it has entered into an agreement to sell the GTX platform to a wholly owned subsidiary of Aurelia Invest AB ("Aurelia"). The transaction is the result of the process initiated in June 2026 to evaluate strategic alternatives for the GTX platform, which was...